data_2lk9_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lk9 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . . . -61.56 -35.51 77.99 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.152 -0.968 . . . . 0.0 109.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . . . -59.28 -40.29 85.62 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.44 -40.16 93.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . . . -61.95 -39.51 83.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.564 -0.963 . . . . 0.0 109.432 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.16 -37.58 73.0 Favored Glycine 0 N--CA 1.493 2.455 0 O-C-N 121.34 -0.85 . . . . 0.0 111.617 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . . . -54.85 -41.99 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.811 -1.405 . . . . 0.0 109.388 -177.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -55.8 -37.19 68.29 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.04 -1.038 . . . . 0.0 110.969 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . . . -58.72 -40.34 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.664 -1.273 . . . . 0.0 110.747 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . . . -58.9 -38.96 80.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.8 -1.187 . . . . 0.0 109.573 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . . . -60.57 -36.61 78.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.069 -1.019 . . . . 0.0 110.192 179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . . . -59.63 -41.06 83.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.014 -1.054 . . . . 0.0 109.239 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . . . -59.99 -40.25 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 120.932 -1.105 . . . . 0.0 110.038 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . . . -60.45 -41.08 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.439 -0.788 . . . . 0.0 111.34 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . . . -63.18 -33.85 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.804 -1.185 . . . . 0.0 109.601 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . . . -60.44 -37.15 80.0 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.201 -0.937 . . . . 0.0 109.451 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.74 -35.27 89.49 Favored Glycine 0 N--CA 1.494 2.548 0 O-C-N 120.845 -1.159 . . . . 0.0 112.382 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . . . -51.33 -54.67 36.08 Favored Pre-proline 0 N--CA 1.504 2.273 0 O-C-N 120.521 -1.576 . . . . 0.0 112.846 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . . . -57.79 -20.3 42.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.509 1.473 . . . . 0.0 111.922 178.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . . . -54.8 -38.85 67.84 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . . . -54.65 -43.35 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.654 -0.819 . . . . 0.0 109.922 -178.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . . . -57.63 -43.93 84.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 120.54 -1.35 . . . . 0.0 109.579 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . . . -61.96 -41.16 97.68 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.092 -1.005 . . . . 0.0 108.975 178.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.589 -0.695 . . . . 0.0 110.074 -179.494 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . . . -61.56 -35.51 77.99 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.152 -0.968 . . . . 0.0 109.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . . . -59.28 -40.29 85.62 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.44 -40.16 93.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . . . -61.95 -39.51 83.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.564 -0.963 . . . . 0.0 109.432 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.16 -37.58 73.0 Favored Glycine 0 N--CA 1.493 2.455 0 O-C-N 121.34 -0.85 . . . . 0.0 111.617 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . . . -54.85 -41.99 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.811 -1.405 . . . . 0.0 109.388 -177.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -55.8 -37.19 68.29 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.04 -1.038 . . . . 0.0 110.969 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . . . -58.72 -40.34 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.664 -1.273 . . . . 0.0 110.747 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . . . -58.9 -38.96 80.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.8 -1.187 . . . . 0.0 109.573 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . . . -60.57 -36.61 78.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.069 -1.019 . . . . 0.0 110.192 179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . . . -59.63 -41.06 83.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.014 -1.054 . . . . 0.0 109.239 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . . . -59.99 -40.25 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 120.932 -1.105 . . . . 0.0 110.038 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . . . -60.45 -41.08 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.439 -0.788 . . . . 0.0 111.34 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . . . -63.18 -33.85 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.804 -1.185 . . . . 0.0 109.601 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . . . -60.44 -37.15 80.0 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.201 -0.937 . . . . 0.0 109.451 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.74 -35.27 89.49 Favored Glycine 0 N--CA 1.494 2.548 0 O-C-N 120.845 -1.159 . . . . 0.0 112.382 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . . . -51.33 -54.67 36.08 Favored Pre-proline 0 N--CA 1.504 2.273 0 O-C-N 120.521 -1.576 . . . . 0.0 112.846 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . . . -57.79 -20.3 42.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.509 1.473 . . . . 0.0 111.922 178.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . . . -54.8 -38.85 67.84 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . . . -54.65 -43.35 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.654 -0.819 . . . . 0.0 109.922 -178.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . . . -57.63 -43.93 84.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 120.54 -1.35 . . . . 0.0 109.579 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . . . -61.96 -41.16 97.68 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.092 -1.005 . . . . 0.0 108.975 178.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.589 -0.695 . . . . 0.0 110.074 -179.494 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 1.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . . . -61.56 -35.51 77.99 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.152 -0.968 . . . . 0.0 109.787 179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . . . -59.28 -40.29 85.62 Favored 'General case' 0 N--CA 1.492 1.665 0 N-CA-C 107.24 -1.392 . . . . 0.0 107.24 -179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.44 -40.16 93.91 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . . . -61.95 -39.51 83.88 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.564 -0.963 . . . . 0.0 109.432 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -56.16 -37.58 73.0 Favored Glycine 0 N--CA 1.493 2.455 0 O-C-N 121.34 -0.85 . . . . 0.0 111.617 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . . . . . . . . . . . -54.85 -41.99 60.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 120.811 -1.405 . . . . 0.0 109.388 -177.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LEU . . . . . . . . . . . . . . . -55.8 -37.19 68.29 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.04 -1.038 . . . . 0.0 110.969 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . . . -58.72 -40.34 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 120.664 -1.273 . . . . 0.0 110.747 -179.037 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . . . -58.9 -38.96 80.08 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.8 -1.187 . . . . 0.0 109.573 -179.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . . . -60.57 -36.61 78.92 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.069 -1.019 . . . . 0.0 110.192 179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . . . -59.63 -41.06 83.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.014 -1.054 . . . . 0.0 109.239 179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ILE . . . . . . . . . . . . . . . -59.99 -40.25 82.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 120.932 -1.105 . . . . 0.0 110.038 179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . . . -60.45 -41.08 86.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.439 -0.788 . . . . 0.0 111.34 -178.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . . . -63.18 -33.85 63.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 120.804 -1.185 . . . . 0.0 109.601 -179.431 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . . . -60.44 -37.15 80.0 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.201 -0.937 . . . . 0.0 109.451 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.74 -35.27 89.49 Favored Glycine 0 N--CA 1.494 2.548 0 O-C-N 120.845 -1.159 . . . . 0.0 112.382 -179.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . . . -51.33 -54.67 36.08 Favored Pre-proline 0 N--CA 1.504 2.273 0 O-C-N 120.521 -1.576 . . . . 0.0 112.846 -176.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' PRO . . . . . . . . . . . . . . . -57.79 -20.3 42.8 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.509 1.473 . . . . 0.0 111.922 178.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . . . -54.8 -38.85 67.84 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . . . -54.65 -43.35 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.654 -0.819 . . . . 0.0 109.922 -178.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . . . -57.63 -43.93 84.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 120.54 -1.35 . . . . 0.0 109.579 -179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . . . -61.96 -41.16 97.68 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.092 -1.005 . . . . 0.0 108.975 178.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.589 -0.695 . . . . 0.0 110.074 -179.494 . . . . . . . . 0 0 . 1 stop_ save_